Form 4: Dogwood Therapeutics Director Acquires Stock Options

Dogwood Therapeutics Director Abel De La Rosa acquired 2,362 stock options with an exercise price of $4.71, aligning his interests with the company's future performance.

Summary

• Abel De La Rosa, a Director of Dogwood Therapeutics, Inc. (DWTX), acquired stock options.
• The transaction occurred on June 27, 2025.
• 2,362 derivative securities (stock options) were acquired.
• Each option has an exercise price of $4.71.
• The options become exercisable on June 27, 2026, and expire on June 27, 2035.
• Following this transaction, Abel De La Rosa directly beneficially owns 2,362 stock options.

Sentiment

Score: 7

Explanation: The acquisition of stock options by a director is generally a positive signal, indicating alignment of interests and potential confidence in future stock price appreciation. The options were granted at $0, which is typical for compensation.

Positives

• Director Abel De La Rosa acquired 2,362 stock options, aligning his interests with the company's future performance.
• The options were acquired at a price of $0, indicating they were likely granted as part of compensation, which can incentivize long-term commitment.

Risks

• The value of the stock options is contingent on Dogwood Therapeutics' common stock price exceeding the exercise price of $4.71.

Future Outlook

This Form 4 filing reports a past transaction and does not provide forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

This insider transaction report is specific to Dogwood Therapeutics, Inc. and does not provide broader industry trends or context.

Related Party Transactions

• The acquisition of stock options by Director Abel De La Rosa represents an equity grant from Dogwood Therapeutics, Inc.

Stakeholder Impact

• Shareholders: Potential positive signal due to the director's increased equity stake and alignment of interests with the company's long-term performance.

Next Steps

• Stock options held by Abel De La Rosa will become exercisable on June 27, 2026.

Key Dates

Keywords

Dogwood Therapeutics, DWTX, SEC Form 4, stock options, insider transaction, director, beneficial ownership, equity compensation